Andet 2024
POS0376 DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS
Udgivelsens forfattere:
- N. Nabi
- Rikke Ibsen
- M. Ibsen
- Jakob Kjellberg
- Merete Lund Hetland
- Bente Glintborg
- Sundhed Sundhed
Udgivelsens forfattere
Om denne udgivelse
Publiceret i
Annals of the Rheumatic Diseases